Alpha Tau Medical Ltd

NASDAQ DRTS

Data sourced from

and

Download Data

Alpha Tau Medical Ltd Cash to Debt Ratio for the Trailing 12 Months (TTM) ending March 31, 2024: 1.58

Alpha Tau Medical Ltd Cash to Debt Ratio is 1.58 for the Trailing 12 Months (TTM) ending March 31, 2024. The cash to debt ratio assesses a company's ability to cover its total debt obligations with its available cash. It is calculated by dividing cash by total debt. This ratio indicates the company's liquidity and its capacity to meet its debt obligations using its cash reserves. A higher cash to debt ratio suggests a stronger ability to cover debts with cash resources.

NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees	121
Sector	Healthcare
Industry	Biotechnology

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends